Sporos and our group of portfolio companies are advancing a diversified pipeline of potential breakthrough therapies. Our focus is on cancer and serious immune disease, and through our vast network of scientific experts, we aim to identify first or best-in-class therapeutic approaches with the potential for significant patient impact.
At Sporos, we are committed to bringing new medicines based on the most advanced scientific knowledge to patients in a safe and efficient manner. Currently, we have one therapeutic candidate in clinical trials and expect to start several more over the coming months.
TTI-101 is currently being evaluated in a Phase 1 clinical trial to evaluate safety and preliminary efficacy in patients with advanced cancers. TTI-101 is an oral STAT3 inhibitor.
STAT3 may be involved in up to 70% of cancers. Abnormal STAT3 activity is associated with cancer cell growth and tumor progression. It is believed to play a significant role in both protecting the tumor from the immune system and directly inhibiting the immune system to keep it from targeting the tumor.
Trial recruitment is currently ongoing. For more information, please visit ClinicalTrials.gov (NCT03195699) for more details.